Vasovist
Vasovist Uses, Dosage, Side Effects, Food Interaction and all others data.
Vasovist is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum albumin.
| Trade Name | Vasovist |
| Generic | Gadofosveset trisodium |
| Gadofosveset trisodium Other Names | Gadofosveset |
| Type | |
| Formula | C33H38GdN3Na3O14P |
| Weight | Average: 957.87 Monoisotopic: 958.10256 |
| Protein binding | 80-90% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Vasovist is an intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.
Vasovist is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Vasovist is also used to associated treatment for these conditions: Aortoiliac Occlusive Disease
How Vasovist works
Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood.
Toxicity
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²).
Food Interaction
No interactions found.Volume of Distribution
48 ± 16 mL/kg
Half Life
18.5 hours
Clearance
6.57 ± 0.97 mL/h/kg following the administration of 0.03 mmol/kg.
Elimination Route
Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%).
Innovators Monograph
You find simplified version here Vasovist
